BR112021026462A2 - Composições e métodos para tratar distúrbios de cns - Google Patents

Composições e métodos para tratar distúrbios de cns

Info

Publication number
BR112021026462A2
BR112021026462A2 BR112021026462A BR112021026462A BR112021026462A2 BR 112021026462 A2 BR112021026462 A2 BR 112021026462A2 BR 112021026462 A BR112021026462 A BR 112021026462A BR 112021026462 A BR112021026462 A BR 112021026462A BR 112021026462 A2 BR112021026462 A2 BR 112021026462A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
cns disorders
treating cns
vib
Prior art date
Application number
BR112021026462A
Other languages
English (en)
Inventor
G Salituro Francesco
Jesus Blanco-Pillado Maria
Lee Morningstar Marshall
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of BR112021026462A2 publication Critical patent/BR112021026462A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

composições e métodos para tratar distúrbios de cns. é aqui fornecido um composto de fórmula i, ii, iiia, iiib, v, via, vib, vii, viii, ix ou xi: ou um sal farmaceuticamente aceitável do mesmo, composições farmacêuticas compreendendo um composto de fórmula i, ii, iiia, iiib, v, via, vib, vii, viii, ix ou x, e métodos para usar os compostos, por exemplo, no tratamento de distúrbios relacionados ao cns.
BR112021026462A 2019-06-27 2020-06-29 Composições e métodos para tratar distúrbios de cns BR112021026462A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867618P 2019-06-27 2019-06-27
PCT/US2020/040153 WO2020264509A1 (en) 2019-06-27 2020-06-29 Compositions and methods for treating cns disorders

Publications (1)

Publication Number Publication Date
BR112021026462A2 true BR112021026462A2 (pt) 2022-03-15

Family

ID=71728947

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026462A BR112021026462A2 (pt) 2019-06-27 2020-06-29 Composições e métodos para tratar distúrbios de cns

Country Status (13)

Country Link
US (1) US20230303616A9 (pt)
EP (1) EP3990469A1 (pt)
JP (1) JP2022538299A (pt)
KR (1) KR20220038680A (pt)
CN (1) CN114391019A (pt)
AR (1) AR119305A1 (pt)
AU (1) AU2020302748A1 (pt)
BR (1) BR112021026462A2 (pt)
CA (1) CA3143509A1 (pt)
IL (1) IL289172A (pt)
MX (1) MX2021015942A (pt)
TW (1) TW202114700A (pt)
WO (1) WO2020264509A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
LT3224269T (lt) 2014-11-27 2020-07-10 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
MX2021014515A (es) 2019-05-31 2022-03-22 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US20090118248A1 (en) * 2004-04-23 2009-05-07 Euro-Celtique S.A. 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
SG11201508550XA (en) * 2013-04-17 2015-11-27 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
CA3086189A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MA54594A (fr) * 2018-12-05 2022-04-06 Sage Therapeutics Inc Stéroïdes neuroactifs et leurs procédés d'utilisation

Also Published As

Publication number Publication date
EP3990469A1 (en) 2022-05-04
US20220380405A1 (en) 2022-12-01
AU2020302748A1 (en) 2022-01-06
WO2020264509A1 (en) 2020-12-30
US20230303616A9 (en) 2023-09-28
IL289172A (en) 2022-02-01
JP2022538299A (ja) 2022-09-01
CN114391019A (zh) 2022-04-22
KR20220038680A (ko) 2022-03-29
AR119305A1 (es) 2021-12-09
CA3143509A1 (en) 2020-12-30
TW202114700A (zh) 2021-04-16
MX2021015942A (es) 2022-04-18

Similar Documents

Publication Publication Date Title
BR112021026445A2 (pt) Composições e métodos para tratar distúrbios de cns
BR112021026462A2 (pt) Composições e métodos para tratar distúrbios de cns
CR20190320A (es) N-[4-fluoro-5[[(2s, 4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il) metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
MX2023002006A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
AR117814A1 (es) Compuestos moduladores de fxr (nr1h4)
BR112021007222A8 (pt) Moduladores de receptor de androgênio e métodos para seu uso
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
AR113908A1 (es) Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
NZ700761A (en) Salt form of a human histone methyltransferase ezh2 inhibitor
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
BR112017025851A2 (pt) compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
DOP2023000251A (es) Compuestos oligoméricos que inhiben la expresión de hsd17b13
BR112021026447A2 (pt) Composições e métodos para tratamento de distúrbios de cns
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
AR097773A1 (es) Compuesto y composición farmacéuticamente aceptable, útil para tratar afección o trastorno mediano por actividad quinurenina 3-mono-oxigenasa
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
EA202193007A1 (ru) Соединения пирролидина